CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
28.67
+0.65 (2.32%)
Dec 20, 2024, 4:00 PM EST - Market closed
CG Oncology Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for CG Oncology stock have an average target of 63.88, with a low estimate of 50 and a high estimate of 75. The average target predicts an increase of 122.81% from the current stock price of 28.67.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CG Oncology stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 5 | 5 | 5 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $66 | Buy | Reiterates | $66 | +130.21% | Dec 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +161.60% | Dec 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +161.60% | Nov 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +161.60% | Nov 12, 2024 |
| UBS | UBS | Strong Buy Initiates $60 | Strong Buy | Initiates | $60 | +109.28% | Oct 24, 2024 |
Financial Forecast
Revenue This Year
535.50K
from 204.00K
Increased by 162.50%
Revenue Next Year
629.85K
from 535.50K
Increased by 17.62%
EPS This Year
-1.34
from -15.65
EPS Next Year
-1.95
from -1.34
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 735,000 | 2.5M | 141.4M | |||
| Avg | 535,500 | 629,850 | 103.5M | |||
| Low | n/a | n/a | 51.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 260.3% | 370.6% | 22,349.8% | |||
| Avg | 162.5% | 17.6% | 16,337.2% | |||
| Low | - | - | 8,021.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.33 | -1.60 | -0.23 |
| Avg | -1.34 | -1.95 | -1.70 |
| Low | -1.38 | -2.29 | -3.03 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.